0001209191-20-055492.txt : 20201021 0001209191-20-055492.hdr.sgml : 20201021 20201021173240 ACCESSION NUMBER: 0001209191-20-055492 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201019 FILED AS OF DATE: 20201021 DATE AS OF CHANGE: 20201021 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Greenberg Norman Michael CENTRAL INDEX KEY: 0001773750 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38935 FILM NUMBER: 201251196 MAIL ADDRESS: STREET 1: 500 SAGINAW DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Atreca, Inc. CENTRAL INDEX KEY: 0001532346 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273723255 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 450 EAST JAMIE COURT CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-595-2595 MAIL ADDRESS: STREET 1: 450 EAST JAMIE COURT CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-19 0 0001532346 Atreca, Inc. BCEL 0001773750 Greenberg Norman Michael C/O ATRECA, INC., 450 EAST JAMIE COURT SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Scientific Officer Class A Common Stock 2020-10-19 4 M 0 500 4.56 A 500 D Class A Common Stock 2020-10-19 4 S 0 500 15.1238 D 0 D Stock Option (right to buy) 4.56 2020-10-19 4 M 0 500 0.00 D 2026-05-09 Class A Common Stock 500 21429 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.19, inclusive. The reporting person undertakes to provide to Atreca, Inc., any security holder of Atreca, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. 1/4 of the Option vested on 5/2/2017 and 1/48 of the Option vests in equal monthly installments as measured from 5/2/2017. The shares subject to this option are early exercisable, subject to the Issuer's right to repurchase. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. /s/ Herbert Cross, attorney-in-fact 2020-10-21